Related Experiment Video
Updated: Jun 25, 2026
10:24
In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions
Published on: June 11, 2015
Relationship between cyclooxygenase-2 inhibition and thrombogenesis
1The Heart Institute, Good Samaritan Hospital, University of Southern California, 1225 Wilshire Boulevard, Los Angeles, CA 90017, USA.
Journal of Cardiovascular Pharmacology and Therapeutics
|April 20, 2004
Summary
Cyclooxygenase-2 (COX-2) inhibitors have complex roles in blood clot formation and heart attack risk. Research shows COX-2
Area of Science:
- Cardiovascular Science
- Pharmacology
- Thrombosis Research
Background:
- Growing interest in cyclooxygenase-2 (COX-2) involvement in thrombosis and myocardial infarction.
- Numerous studies investigate whether COX-2 inhibitors increase cardiovascular thrombosis risk.
- Understanding COX-2's role is crucial for cardiovascular health management.
Purpose of the Study:
- To review the multifaceted roles of COX-2 in prostaglandin metabolism.
- To analyze the impact of COX-2 inhibition on platelet aggregation and endothelial antithrombotic function.
- To evaluate COX-2 inhibition's effects on atherothrombosis and myocardial infarction risk through clinical trials.
Main Methods:
- Comprehensive literature review of clinical and basic science studies.
- Analysis of data on prostaglandin metabolism and COX-2.
- Examination of studies on platelet aggregation, vascular endothelium, and atherothrombosis.
- Review of clinical trial outcomes related to COX-2 inhibition and myocardial infarction.
Main Results:
- COX-2 exhibits varied and sometimes contradictory roles in thrombogenesis.
- COX-2 inhibition influences prostaglandin metabolism in endothelium under different conditions.
- The impact of COX-2 inhibition on atherothrombosis is complex and requires further study.
- Clinical trial data present a controversial picture regarding COX-2 inhibition and cardiovascular risk.
Conclusions:
- COX-2's role in cardiovascular thrombosis is diverse and not fully elucidated.
- Further research is needed to clarify the net effect of COX-2 inhibition on thrombogenesis.
- Understanding these complex roles is essential for guiding clinical practice and patient care.
Related Concept Videos
01:16Cycloaddition Reactions: MO Requirements for Thermal Activation
Thermal cycloadditions are reactions where the source of activation energy needed to initiate the reaction is provided in the form of heat. A typical example of a thermally-allowed cycloaddition is the Diels–Alder reaction, which is a [4 + 2] cycloaddition. In contrast, a [2 + 2] cycloaddition is thermally forbidden.
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.